Filing Flows › Gyre Therapeutics (GYRE) › Q2 2026 › vs Q2 2025
Gyre Therapeutics (GYRE) Q2 2026 vs Q2 2025 (year over year)
Gyre Therapeutics's revenue fell $629K (-2%) from $29.7M in Q2 2025 to $29.1M in Q2 2026. The biggest changes: Gyre −$3.0M (-100%); Gyre Pharmaceuticals +$2.3M (+9%).
Gyre Therapeutics, Q2 2026: revenue $29.1M (-2% year over year), operating margin -49.3%, net loss $23.0M, operating cash flow −$16.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Gyre Pharmaceuticals | $29.1M | $26.8M | $2.3M | +9% |
| Gyre | $8K | $3.0M | −$3.0M | -100% |
| Revenue | $29.1M | $29.7M | −$629K | -2% |
| Income tax benefit | $164K | −$662K | $826K | — |
| Net loss | $23.0M | $1.0M | $22.0M | 22× |
| Costs & expenses | $52.3M | $32.6M | $19.6M | +60% |
| Operating costs | $43.5M | $32.0M | $11.5M | +36% |
| Interest & other, net | $8.8M | −$1.9M | $10.7M | — |
| SG&A | $7.9M | $7.3M | $587K | +8% |
| Other operating costs | $33.4M | $12.2M | $21.2M | +173% |
| Operating cash sources | $23.0M | $1.0M | $22.0M | 22× |
| Depreciation & amortization | $1.5M | $1.0M | $474K | +47% |
| Share-based compensation | $2.1M | $1.4M | $639K | +44% |
| Working capital & other | $2.7M | −$8.9M | $11.6M | — |
| Cash used in operations | $16.7M | $7.5M | $9.3M | +124% |
| Net loss absorbed | $23.0M | $1.0M | $22.0M | 22× |
Questions
How much did Gyre Therapeutics's revenue grow year over year in Q2 2026?
Gyre Therapeutics's revenue fell $629K (-2%) from $29.7M in Q2 2025 to $29.1M in Q2 2026.
What drove Gyre Therapeutics's revenue change in Q2 2026?
Gyre −$3.0M (-100%); Gyre Pharmaceuticals +$2.3M (+9%).